Last --
Change Today 0.00 / 0.00%
Volume 0.0
4527 On Other Exchanges
Symbol
Exchange
4527 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

rohto pharmaceutical co ltd (4527) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ROHTO PHARMACEUTICAL CO LTD (4527)

Related News

No related news articles were found.

rohto pharmaceutical co ltd (4527) Related Businessweek News

No Related Businessweek News Found

rohto pharmaceutical co ltd (4527) Details

ROHTO Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods in Japan and internationally. The company’s eye care products comprise eye drops, eye wash preparations, and contact lens care products; and skin care products include dermal medicines, lip care, and hand/body/sun/acne care products, as well as other skin care products, such as deodorant liquid sprays, deoseptic lotions, and essences. Its internal use medicines comprise Pansiron brand medicines for overdrinking, nausea, vomiting, stomach discomfort, over-eating, indigestion, promotion of digestion, dyspepsia, heartburn, stomach pain, hyperacidity, belching, heaviness in the stomach/chest, and feeling of fullness in the stomach and abdomen. The company’s internal use medicines also include cold remedies for cold symptoms and antitussive syrups; other internal medicines for rest, constipation, cold, nasal discharge, and sneezing; supplements for body, skin, and blood sugar levels, as well as for fat diet and daily meals; and other internal use medicines for clean intestine environment. In addition, it offers test kits, such as OTC pregnancy and diagnostic test kits; Hay fever products for the treatment of stuffy or runny nose due to allergic rhinitis; and denture cleanser products for daily sanitation of dentures and mouth, and nicotine or tar stains. The company was formerly known as Yamada Pharmaceutical and changed its name to ROHTO Pharmaceutical Co., Ltd. in 1949. ROHTO Pharmaceutical Co., Ltd. was founded in 1899 and is headquartered in Osaka, Japan.

5,845 Employees
Last Reported Date: 06/25/14
Founded in 1899

rohto pharmaceutical co ltd (4527) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥144.0M
Compensation as of Fiscal Year 2012.

rohto pharmaceutical co ltd (4527) Key Developments

Rohto Pharmaceutical Co., Ltd. to Report Q1, 2015 Results on Aug 07, 2014

Rohto Pharmaceutical Co., Ltd. announced that they will report Q1, 2015 results on Aug 07, 2014

International Stem Cell Corporation Inks Deal Including Certain Terms for Definitive License Agreement with Rohto Pharmaceutical

International Stem Cell (ISCO) has entered into a research agreement with Rohto Pharmaceutical (Rohto). As part of the deal, Rohto will assess stem cell-derived human cells owned and provided by ISCO in a number of pre-clinical animal models. The company said that if the research is successful and the parties agree on remaining terms, it is expected that a definitive license agreement will be signed at the end of the twelve-month period of this research agreement. ISCO EVP of Business Development Simon Craw said under the terms of the agreement Rohto will begin working with ISCO provided cells immediately and if the program is successful the company may move to the next stage, signing a definitive license agreement. The deal will see ISCO offer a number of differentiated human cells derived from the company's collection of pluripotent human stem cells known as UniStemCell.

International Stem Cell Corporation Enters into Research Agreement with Rohto Pharmaceutical Co., Ltd

International Stem Cell Corporation (ISCO) announced that it has entered into a research agreement with Rohto Pharmaceutical Co., Ltd. Under this agreement, Rohto will evaluate stem cell-derived human cells owned and provided by ISCO in a number of pre-clinical animal models. If the research is successful and the parties agree on remaining terms, it is anticipated that a definitive license agreement will be signed at the end of the twelve-month period of this research agreement. Certain key terms of such a license agreement, including the target disease areas and intellectual property rights, have been established in the research agreement. Under the agreement ISCO will provide a number of differentiated human cells derived from the company's collection of pluripotent human stem cells known as UniStemCell(TM). The company has a track record of successfully demonstrating that human cells derived from UniStemCell(TM) are effective in animal models of various diseases and have the potential to be used as a basis for developing human therapies.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4527:JP ¥1,456.00 JPY -20.00

4527 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4527.
View Industry Companies
 

Industry Analysis

4527

Industry Average

Valuation 4527 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROHTO PHARMACEUTICAL CO LTD, please visit www.rohto.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.